




FK-S06 Enhances Cyclosporine Uptake by Peripheral 
Blood Lymphocytes 
A. Sanghvi, V. Warty, A. Zeevi, W. Diven, R. Duquesnoy, L. Makowka, and T.E. Starzl 
T HE PROCESS of cellular uptake and 
metabolism of cyclosporine (CsA) is 
poorly understood. Previously, we have shown 
that the transport of CsA in blood occurs in 
association with plasma Iipoproteins,l with 
low-density lipoprotein (LOL), and with high-
density lipoprotein, each transporting about 
32% of the total amount of CsA in blood. This 
observation raises the possibility that further 
cellular metabolism of CsA, at least in part, 
may take place in conjunction with LOL 
metabolism through its specific, high-affinity 
cell surface receptor. In this report, we present 
results of studies that indicate that (1) [lH]_ 
labeled CsA is taken up, in an apparently 
specific manner, by peripheral blood lympho-
cytes (PBL) when incubated with the [lH] 
CsA-LOL complex; and (2) cellular uptake 
of [lH] CsA is enhanced when PBL, whether 
freshly isolated or stimulated with phyto-
hemagglutinin (PHA), are incubated in a 
medium containing both [lH] CsA and FK-
506 (FK) in a 1:1 (wt/wt) proportion. 
MATERiAlS AND METHODS 
Tritiated dihydrocyclosporine A (60 mCi/mmoI) and 
CsA standards were obtained from Sandoz, Ltd (Basel, 
Switzerland) as ethanolic solutions. FK was a gift from 
Fujisawa Pharmaceutical Co, Ltd (Osaka, Japan). 
Methanolic solution of FK was used in the experiments. 
Culture media and antibiotics were obtained from 
GlBCO (Grand Island, NY). All other reagents and 
supplies were from Fisher Scientific Co, Pittsburgh. 
Lipoproteins 
Human LOL (d, 1.019 to 1.063) was prepared from 
blood collected in 0.1 % EOT A from healthy subjects who 
had fasted overnight. Lipoproteins were fractionated by 
sequential ftoatation in a Beckman preparative ultracen-
trifuge (Beckman Instruments, Inc, Fullerton, CAl 
according to Havel et aJ.2 Protein determinations were 
performed by the Bradford method.' 
Cells 
Peripheral blood mononuclear cells were isolated as 
previously described· from approllimately 100 mL of 
blood obtained from healthy volunteers for each experi-
ment. The monocyte content of these cells was depleted 
by the method of Jerrells et al. S Cell viability was assessed 
by using the dye ellclusion method.' 
PHA-Induced Activation of PBL 
Lymphocyte cultures were set up in 24-well cluster 
plates (5 x 10' cells/well) in 1 mL of tissue culture 
medium supplemented with 10% human serum, 20% 
interleukin-2, and PHA (0.0125 I'g/mL). After 96 hours, 
the cells were harvested and washed twice and the cell 
concentration determined. 
Alloreactive T cell clones were generated from mixed 
lymphocyte cultures. The uptake of CsA by these cells in 
various experiments was determined as described in the 
following sections. 
Lipoprotein-CsA Complex 
LOL (100 I'g in I mL RPMI 1640 medium) was added 
dropwise with stirring to an ethanolic ['H) CsA solution 
(SO I'L). The mixture was incubated with constant shak-
ing for one hour at room temperature. The specific 
activity of the [3H] CsA-LOL oomplex thus obtained in 
three separate preparations was 20 ± 0.8 x ut dpm/I'g 
LOL. The purity of LOL was assessed by sodium dodecyl 
sulfate gel electrophoresis. 
CsA Uptake by PBL 
Lymphocytes were incubated in RPM I 1640 medium 
containing 1 % bovine serum albumin (BSA) in the pres-
ence or absence of C,A and/or FK for 24 hours. After 
these preincubations, the cells were washed twice with 
ice-cold 0.85% NaCI solution and then resuspended in 1 % 
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BSA·RPMI m~-dium. The cells were placed in culture 
wells (approximately 10' cells/well) and exposed to 
increasing molar concentrations of ['HJ CsA (specific 
activity. 900 to 1.100 dpm/pmol) and equivalent concen· 
trations of cold CsA and FK. as indicated in the legends to 
the figures. for one hour at 37°C in the humidified 
atmosphere of 95% O 2:5% COl' Transport flux was 
stopped by adding ice-cold saline and cooling the mixture 
further for ten minutes over ice. The cells were washed 
three times with cold saline and incubated in 0.2 mL i N 
KOH for one hour at 70°C. The digested solution was 
used for the measurement of radioactivity and protein 
determinations. 
The cell content of FK was measured by an enzyme 
immunoassay method obtained from Fujisawa. 
In experiments when the [lH] CsA-LOL complex was 
used, the results are expressed as picomoies of CsA 
accumulated per milligram cell protein as a function of 
micrograms of LOL protein and the corresponding 
amount of ['H] CsA contained in the ['HJ CsA-LOL 
complex. Nonspecific (receptor-independent) binding of 
LOL to the cells in these experiments was determined by 
incubating the cells in the presence of IOO-fold excess of 
cold LOL as well as cold CsA. 
RESULTS 
CsA uptake by lymphocytes from two 
healthy donors was studied by incubating cells 
with the [3H] CsA-LDL complex. The kinet-
ics of the uptake of CsA in these experiments 
are shown in Fig 1, panels A and B. In both 
individuals studied, the CsA uptake appears 
to reach saturation at an LDL concentration 
of about 50 J.LgjmL medium. The correspond-
ing CsA concentration is about 900 ng/mL. In 
a previous study4 on the cell surface binding 
and subsequent metabolism of LDL by T and 
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LDL receptor is saturated at 50 J.Lg LDLjmL 
medium. Moreover, eHJ CsA uptake by lym-
phocytes was suppressed in the presence of 
cold CsA and LDL. Combined, these observa-
tions suggest that internalization of lipopro-
tein-associated CsA may occur via the high-
affinity specific receptor for LDL on the cell 
surface. The experimental conditions used in 
these studies imply that the CsA measure-
ments shown reflect both the processes of cell 
surface binding and internalization. 
Cell u la r CsA uptake in the a bsence of LD L 
was studied in lymphocytes from two healthy 
volunteers (other than for Figs 1 and 2). The 
results of the experiments shown in Fig 2, 
panels A and B, indicate that; as in the 
presence of LDL, [lH] CsA uptake in this 
instance may also involve a saturable process. 
Because a specific cell surface receptor for 
CsA has not been identified to date whereas 
characteristics of a. specific cytosolic pro-
tein~ycJophilin7-that binds CsA have been 
described, the data in Figs 3 and 4 may be 
most compatible with the binding of internal-
ized CsA to cycJophilin or similar protein(s).8 
When a 100-fold excess of cold CsA was 
included in these incubations. the cellular 
uptake of labeled CsA declined significantly, 
which suggested a competitive process. The 
same was true when a lOO-fold excess of FK 
(with respect to the [3H] CsA concentration) 
was present in the incubations_ These data 
would imply that both FK and CsA may be 
competing for binding to the same cytosolic 
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Fig 1_ Cellular uptake of 
CsA in PSl incubated with the 
['HI CsA-lDl complex for one 
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A B 
Fig 2. Cellular uptake of 
CsA in PBl incubated with ['HI 
CsA (0--<)' and in the pres-
ence of a tOO-fold excesa of FK 
(t;-t;) and unlabeled CsA 
( ... - ... ,. Panels A and Bare 
results in two subjects. 
0,5 1,0 ZO 
~L OSPOMCE ",10-' 1111 
0.5 1'0 Z,(, '1.0 
CYCLOSPORINE (,.,0 .... ' 
components, though not necessarily the same 
'!Sites. 
In Fig 3 are shown the effects of including 
equivalent amounts of either FK or cold CsA 
(1:1, wt/wt) together with [3Hl CsA at each 
point in the incubation medium on the cellular 
uptake of [3H] CsA (panel A). For panels B 
and C, the experimental conditions were iden-
tical to those in panel A except that cells were 
preincubated for 24 hours with either 10 Ilg 
CsA/mL (panel B) or with 1 Ilg FK/mL 
(panel C). Subsequently. the cells were 
washed and incubated with [lH] CsA as 
described in Materials and Methods. Under 
all three conditions, the cellular uptake of 
[3H] CsA was higher at each concentration of 
[3H] CsA in the incubation in the presence of 
equivalent amounts of FK than in its absence. 
When the cells are preincubated with 10 Ilg 
CsA, the absolute uptake of [3H] CsA is 
reduced in all cases relative to panels A and C, 
thereby suggesting that some of the cellular 
A B 
'00 
CsA binding sites are taken up by unlabeled 
CsA. However, even under these conditions, 
inclusion of FK in the medium is able to 
induce a higher [lH] CsA uptake. Preincuba-
tion of cells in the presence of 1 Ilg FK does 
not seem to significantly stimulate further the 
increased CsA uptake (panel C). 
PHA-stimulated lymphocytes exhibit a 
generally increased [3H] CsA uptake (Fig 4, 
panels A, B, and C), compared with unstimu-
lated cells. Conditions for these experiments 
were identical to those for experiments in Fig 
3 except that preincubations with 10 Ilg CsA 
and 1 I'g FK/mL of medium were for 72 
hours. Again, the uptake of PH] CsA is 
enhanced when the incubations contain 
amounts of FK equivalent to the amounts of 
[3H] CsA at each point. . 
DISCUSSION 
Several results presented here support the 
following observations: (I) the drug FK, when 
c 
1.0 1.0 4.0 
~t"I~1 
Fig 3. lymphocytel were preincubated in ", BSA in RPMI (panel A) and 1% BSA in RPMI containing 101'9 
CIA/ml (panel B, or 1 lig FK/ml (panel C) for 24 hours. The cellula. uptake of rtf! CsA was then measured in the 
absence (0--<)) and presence of equivalent amounts of FK (t;-t;) and cold CIA ( ... - ... , • .-. indicates 
displacement of rtf) CaA in the preaence of a 100-fold exce .. of cold CaA. 
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Fig 4. Lymphocytes were preincubeted in RPMI medium containing PHA (panel AI. and 10 I'g CsA I mL (panel BI 
and 1 I'g FKI ml (panel CI for 72 hours. The cellular uptake of rHI CsA was then measured in the absence (~I 
and presence of equivalent amounts of FK (fl.-fl.1 and cold CsA (.t.-.). 
present in incubations of lymphocytes with 
[JH] CsA in equivalent concentrations, 
enhances the cellular uptake of CsA; and (2) 
the cellular uptake of CsA appears to involve 
both specific as well as nonspecific processes, 
the former taking place when the drug is 
associated with lipoprotein. In this instance, 
the CsA-LDL complex may be interiorized 
via the high-affinity, specific cell surface 
receptor for LDL. Support for this concept 
derives partly from the calculations of disso-
ciation constants for various experiments 
reported here. The double reciprocal plots of 
data9 from these experiments yield two quite 
distinct apparent dissociation constants (KD). 
For the cellular uptake of CsA complexed 
with LDL, KD - 2.3 and 0.6 x 10-9 mol/L 
(Fig 1, panels A and B, respectively). For the 
data in all of the rest of the experiments, KD -
2 X 10-7 mol/L (Table 1). The Ko of 10-9 
mol/L for CsA when in association with LDL 
certainly suggests high-affinity binding. The 
Table 1. Binding of C.A to lymphocytes 
Experiment 
A. ['H) CsA-LOL + PBl (Fig 1) 
B. rH) CsA + PBl (Figs 2 and 3) 
+ FK (Fig 3) 
c. eH) CsA + PHA-1Itimulated PBL 
+ FK (Fig 4) 
K., (moIIL) 
2.3 x 10-1 
0.6 x 10-" 
2.0 :!: 0.5 X 10-7 
1.9:!: 0.3 x 10-7 
2.0 :!: 0.3 X 10-7 
2.1 ± 0.1 x 10-7 
For experiments B and C, the values expressed are 
means ± SO; n - 5 and 3, respectively. 
rate-limiting step in the LDL pathway is the 
binding of LDL to a specific high-affinity 
receptor on the cell surface. 'o It may be 
expected, therefore, that this would be the 
initial step in the metabolism ofCsA bound to 
LDL. The significantly reduced cellular con-
tent of [JH] CsA in the presence of cold LDL 
appears to strengthen this view. Whether such 
a binding of CsA-LDL to the LDL receptor 
followed by further metabolism along the 
LDL pathway occurs cannot be inferred from 
the experiments reported here. If true, how-
ever. it could represent a significant pathway 
for CsA metabolism because some 32% of the 
drug in blood is bound to plasma LDL. ' The 
concentrations of CsA required to saturate the 
Table 2. Effect of Preincubation of PBl With FK on the 
Cellular Content of the Drug 
FK (ngt 1(" Cells) 
Subject Controj' Experimental· 
B. 0.05 0.07 
b. 0.12 0.25 
2 a. 0.19 0.38 
b. 0.20 0.79 
3 a. 0.49 0.69 
b. 1.58 Not measured 
PSl were preincubated for 24 hours in 1 % BSA with and 
without (control) 1 I'g FK/ml medium. 
• After preincubation and washings, control and experi-
mental cells were incubated with 1 and 4 x 10-7 mol/L, a 
and b respectively, concentrations of FK for one hour. The FK 
content in the cells was meas ... ed by enzym ...... inked immu-
nosorbent assay. 
c 
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cellular mechanism(s) responsible for esA 
uptake are also different in the presence and 
absence of LDL, 900 ng/mL with LDL and 
about 300 ng/mL without LDL. This infor-
mation further segregates the two processes. 
The Ko of 2 x 10-7 mol/L when eH] esA 
is incubated with lymphocytes in the absence 
of LDL is strikingly similar to the reported 
Ko's for esA binding to cyclophilin,7 calmo-
dulin," and perhaps other cytosolic proteins. 8 
This similarity implies that what is being 
measured in these experiments (ie, in the 
49 
absence of LDL) is the binding of [JH] esA to 
cytosolic proteins after internalization. 
Although the uptake of eH J esA is 
increased in the presence of FK, Ko remains 
unchanged (Table I). How FK promotes esA 
uptake by lymphocytes is not presently 
known. In preliminary experiments, we have 
observed that cells incubated with FK under 
various conditions accumulate the drug intra-
cellularly (Table 2). The kinetics of the pro-
cess of cellular uptake of FK are currently 
being investigated. 
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